527 related articles for article (PubMed ID: 25148595)
1. Structure-based virtual screening of the nociceptin receptor: hybrid docking and shape-based approaches for improved hit identification.
Daga PR; Polgar WE; Zaveri NT
J Chem Inf Model; 2014 Oct; 54(10):2732-43. PubMed ID: 25148595
[TBL] [Abstract][Full Text] [Related]
2. Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights into agonist binding and activation.
Daga PR; Zaveri NT
Proteins; 2012 Aug; 80(8):1948-61. PubMed ID: 22489047
[TBL] [Abstract][Full Text] [Related]
3. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
Zaveri NT; Journigan VB; Polgar WE
ACS Chem Neurosci; 2015 Apr; 6(4):646-57. PubMed ID: 25635572
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP.
Zaveri N; Jiang F; Olsen C; Polgar W; Toll L
AAPS J; 2005 Oct; 7(2):E345-52. PubMed ID: 16353914
[TBL] [Abstract][Full Text] [Related]
5. "In silico" study of the binding of two novel antagonists to the nociceptin receptor.
Della Longa S; Arcovito A
J Comput Aided Mol Des; 2018 Feb; 32(2):385-400. PubMed ID: 29340866
[TBL] [Abstract][Full Text] [Related]
6. Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists.
Meyer ME; Doshi A; Yasuda D; Zaveri NT
AAPS J; 2021 May; 23(3):68. PubMed ID: 33974173
[TBL] [Abstract][Full Text] [Related]
7. Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement.
Pala D; Beuming T; Sherman W; Lodola A; Rivara S; Mor M
J Chem Inf Model; 2013 Apr; 53(4):821-35. PubMed ID: 23541165
[TBL] [Abstract][Full Text] [Related]
8. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic.
Thompson AA; Liu W; Chun E; Katritch V; Wu H; Vardy E; Huang XP; Trapella C; Guerrini R; Calo G; Roth BL; Cherezov V; Stevens RC
Nature; 2012 May; 485(7398):395-9. PubMed ID: 22596163
[TBL] [Abstract][Full Text] [Related]
9. Probing ligand recognition of the opioid pan antagonist AT-076 at nociceptin, kappa, mu, and delta opioid receptors through structure-activity relationships.
Journigan VB; Polgar WE; Tuan EW; Lu J; Daga PR; Zaveri NT
Sci Rep; 2017 Oct; 7(1):13255. PubMed ID: 29038479
[TBL] [Abstract][Full Text] [Related]
10. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
[TBL] [Abstract][Full Text] [Related]
11. Discovery and structure-activity relationships (SAR) of a novel class of 2-substituted N-piperidinyl indole-based nociceptin opioid receptor ligands.
Meyer ME; Doshi A; Polgar WE; Zaveri NT
Bioorg Med Chem; 2023 Sep; 92():117421. PubMed ID: 37573822
[TBL] [Abstract][Full Text] [Related]
12. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.
Zaveri NT; Jiang F; Olsen C; Polgar WE; Toll L
Bioorg Med Chem Lett; 2013 Jun; 23(11):3308-13. PubMed ID: 23623415
[TBL] [Abstract][Full Text] [Related]
13. Discovery of small-molecule nonpeptide antagonists of nociceptin/orphanin FQ receptor: The studies of design, synthesis, and structure-activity relationships for (4-arylpiperidine substituted-methyl)-[bicyclic (hetero)cycloalkanobenzene] derivatives.
Hayashi S; Ohashi K; Mihara S; Nakata E; Emoto C; Ohta A
Eur J Med Chem; 2016 May; 114():345-64. PubMed ID: 27043173
[TBL] [Abstract][Full Text] [Related]
14. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological activity of small peptides as NOP and opioid receptors' ligands: view on current developments.
Naydenova E; Todorov P; Zamfirova R
Vitam Horm; 2015; 97():123-46. PubMed ID: 25677770
[TBL] [Abstract][Full Text] [Related]
16. The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands.
Jong L; Zaveri N; Toll L
Bioorg Med Chem Lett; 2004 Jan; 14(1):181-5. PubMed ID: 14684324
[TBL] [Abstract][Full Text] [Related]
17. A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor.
Zaveri NT; Jiang F; Olsen CM; Deschamps JR; Parrish D; Polgar W; Toll L
J Med Chem; 2004 Jun; 47(12):2973-6. PubMed ID: 15163178
[TBL] [Abstract][Full Text] [Related]
18. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
19. Differential In Vitro Pharmacological Profiles of Structurally Diverse Nociceptin Receptor Agonists in Activating G Protein and Beta-Arrestin Signaling at the Human Nociceptin Opioid Receptor.
Lu JJ; Polgar WE; Mann A; Dasgupta P; Schulz S; Zaveri NT
Mol Pharmacol; 2021 Jul; 100(1):7-18. PubMed ID: 33958480
[TBL] [Abstract][Full Text] [Related]
20. Rapid access towards follow-up NOP receptor agonists using a knowledge based approach.
Palin R; Clark JK; Evans L; Feilden H; Fletcher D; Hamilton NM; Houghton AK; Jones PS; McArthur D; Montgomery B; Ratcliffe PD; Smith AR; Sutherland A; Weston MA; Wishart G
Bioorg Med Chem Lett; 2009 Nov; 19(22):6441-6. PubMed ID: 19818611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
